

(12)

EUROPEAN PATENT APPLICATION

(43)

Date of publication:  
02.04.2003 Bulletin 2003/14

(51)

Int Cl.7: A61K 9/14

(21)

Application number: 02256741.6

(22)

Date of filing: 27.09.2002

<div>(84)</div> <div>Designated Contracting States: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR Designated Extension States: AL LT LV MK RO SI</div>	<div>(72)</div> <div>Inventors:<ul style="list-style-type: none"><li>Szymczak, Christopher E. Marlton, NJ 08053 (US)</li><li>Walter, James T. Ambler, PA 19002 (US)</li></ul></div>
<div>(30)</div> <div>Priority: 28.09.2001 US 966441</div>	<div>(74)</div> <div>Representative: Mercer, Christopher Paul et al Carpmaels &amp; Ransford 43, Bloomsbury Square London WC1A 2RA (GB)</div>
<div>(71)</div> <div>Applicant: McNEIL-PPC, INC. Skillman, NJ 08858 (US)</div>	

(54)

Simethicone solid oral dosage form

(57)

The present invention provides a composition for forming a compressed solid dosage form that is a free-flowing compressible admixture of simethicone, an adsorbant, and an optional active agent, wherein the weight ratio of simethicone to adsorbent is at least 1: 2.22. Also included are solid dosage forms made from

a free-flowing compressible admixture of simethicone, an adsorbant, and an optional active agent, wherein the weight ratio of simethicone to adsorbent is at least 1: 2.22.

## Description

## FIELD OF THE INVENTION

5 **[0001]** The present invention is directed to a free-flowing compressible composition containing simethicone and an adsorbent for forming a solid dosage form, such solid oral dosage forms and related processes.

## BACKGROUND OF THE INVENTION

10 **[0002]** Active agents, e.g., pharmaceuticals, nutraceuticals, and the like, intended for oral administration are often provided in solid form as tablets, capsules, pills, lozenges, or granules. Oral dosage forms are swallowed whole, chewed in the mouth, disintegrated in the mouth and swallowed, or dissolved sublingually.

**[0003]** When administered orally, simethicone is used as an adjunct in the symptomatic treatment of flatulence, functional gastric bloating, and postoperative gas pains. The clinical use of simethicone is based on its antifoam properties. Silicone antifoams spread on the surface of aqueous liquids, forming a film of low surface tension and thus causing the collapse of foam bubbles. Thus, for self medication in over-the-counter preparations, simethicone is used as an antifatulent to relieve symptoms commonly referred to as gas, including upper GI bloating, pressure, fullness, or stuffed feeling. It is often combined with other gastrointestinal medications, such as antacids, antispasmodics or digestive enzymes and various simethicone formulations are previously disclosed.

20 **[0004]** Simethicone can be administered orally as a liquid preparation or as solid form for example capsules, chewable or swallowable tablets. The advantage of tablets over liquids is the ease of portability. The advantages of swallowable tablets over chewable tablets include the ease of ingestion and lack of taste. Coated tablets are preferred for swallowable tablets.

**[0005]** Historically, in preparing solid simethicone dosage forms, difficulties have been encountered when attempting to incorporate substantial quantities of the liquid simethicone in the solid final blend for tableting. The difficulty has been to achieve sufficient flowability for processing and sufficient cohesion for compaction, particularly for direct compression tableting, so that the tablet will withstand the rigors of further processing, e.g., film coating, gelatin dipping, printing, packaging and the like. Likewise, difficulties have been encountered in assuring that the viscous liquid simethicone is uniformly distributed throughout the solid formulation and expeditiously dispersed upon administration.

30 **[0006]** Japanese Patent No. SHO 39[1961]-46451 to Kitsusho Yakuhin Kogyo KK discloses a method for preparing simethicone tablets by mixing and granulating simethicone with aluminium silicate, magnesium aluminum metasilicate, and magnesium silicate. In particular, the formulation disclosed by the above Japanese patent requires at most 25 % simethicone and 75% or greater silicate, binder and dispersing agent. Binders were disclosed as being starch and lactose. Dispersing agent was disclosed as being carboxymethylcellulose. Further, the above Japanese patent discloses that when the amount of simethicone exceeds 25%, a portion of the simethicone can be carried away, therefore the tablet workability is not desirable.

**[0007]** JP 5097681 to Horii Yakuhin Kogyo KK discloses a preparation wherein simethicone is adsorbed to magnesium aluminate metasilicate and dextrin. Excipient was then added and the preparation was tableted. Following tableting a hydroxypropyl methylcellulose phthalate coating was added, followed by applying additional simethicone and gelatin. The amount of simethicone in the final tablet was about 15%.

40 **[0008]** U.S. Patent No. 4,906,478 discloses a simethicone preparation including a powdered combine of particulate calcium silicate and simethicone. U.S. Patent No. 5,073,384 discloses simethicone preparations including combines of water soluble agglomerated maltodextrin and simethicone. U.S. Patent No. 5,458,886 discloses a free-flowing granular composition including titanium dioxide having specific particle size and surface area in combination with simethicone.

45 **[0009]** US Patent No. 6,103,260 describes the use of an admixture of simethicone and either one or both of granular anhydrous tribasic calcium phosphate or dibasic calcium, wherein the admixture in a uniform granular composition of not more than 1000 micron particle size, that is suitable for compression into a solid dosage form for oral administration. While the amount of simethicone in the final composition was disclosed as being 10% to 50%, the final tablet weight was in excess of 1000 mg.

50 **[0010]** What is needed, therefore, is a free-flowing compressible composition containing simethicone for forming a solid dosage, wherein either larger quantities of simethicone can be incorporated therein or smaller solid dosage forms containing the same amount of simethicone.

55 **[0011]** Surprisingly, it has been discovered that using silicified microcrystalline cellulose and magnesium aluminometasilicate as substrates onto which simethicone or other oil or liquid active is adsorbed provides such a composition. Thus, there is provided by the present invention a free-flowing compressible composition containing simethicone for forming a solid dosage form that contains either larger weight percentages of simethicone while maintaining substantially the same size than previously possible or the same weight percentage of simethicone in a smaller size. In

addition, the present invention is directed to such solid oral dosage forms and related processes.

## SUMMARY OF THE INVENTION

**[0012]** The present invention provides a composition for forming a compressed solid dosage form that is a free-flowing compressible admixture of simethicone, an adsorbant, and an optional active agent, wherein the weight ratio of simethicone to adsorbent is at least 1:2.22. Also included are solid dosage forms made from a free-flowing compressible admixture of simethicone, an adsorbant, and an optional active agent, wherein the weight ratio of simethicone to adsorbent is at least 1:2.22.

## DETAILED DESCRIPTION OF THE INVENTION

**[0013]** The term, "active agent" is used herein in a broad sense and encompasses any material that can be carried by or entrained in the system. For example, the active agent can be a pharmaceutical, nutraceutical, vitamin, dietary supplement, nutrient, or the like and combinations thereof.

**[0014]** The active agents useful herein can be selected from classes from those in the following therapeutic categories: ace-inhibitors; alkaloids; antacids; analgesics; anabolic agents; anti-anginal drugs; anti-allergy agents; anti-arrhythmia agents; antiasthmatics; antibiotics; anticholesterolemics; anticonvulsants; anticoagulants; antidepressants; antidiarrheal preparations; anti-emetics; antihistamines; antihypertensives; anti-infectives; anti-inflammatories; antilipid agents; antimanics; anti-migraine agents; antinauseants; antipsychotics; antistroke agents; antithyroid preparations; anabolic drugs; antiobesity agents; antiparasitics; antipsychotics; antipyretics; antispasmodics; antithrombotics; antitumor agents; antitussives; antiulcer agents; anti-uricemia agents; anxiolytic agents; appetite stimulants; appetite suppressants; beta-blocking agents; bronchodilators; cardiovascular agents; cerebral dilators; chelating agents; cholecystokinin antagonists and agonists; chemotherapeutic agents; cognition activators; contraceptives; coronary dilators; cough suppressants; decongestants; deodorants; dermatological agents; diabetes agents; diuretics; emollients; enzymes; erythropoietic drugs; expectorants; fertility agents; fungicides; gastrointestinal agents; growth regulators; hormone replacement agents; hyperglycemic agents; hypoglycemic agents; ion-exchange resins; laxatives; migraine treatments; mineral supplements; mucolytics, narcotics; neuroleptics; neuromuscular drugs; non-steroidal anti-inflammatories (NSAIDs); nutritional additives; peripheral vasodilators; polypeptides; prostaglandins; psychotropics; renin inhibitors; respiratory stimulants; sedatives; steroids; stimulants; sympatholytics; thyroid preparations; tranquilizers; uterine relaxants; vaginal preparations; vasoconstrictors; vasodilators; vertigo agents; vitamins; wound healing agents; and others.

**[0015]** Active agents that may be used in the invention include, but are not limited to: acetaminophen; acetic acid; acetylsalicylic acid, including its buffered forms; acrivastine; albuterol and its sulfate; alcohol; alkaline phosphatase; allantoin; aloe; aluminum acetate, carbonate, chloral hydrate; alprazolam; amino acids; aminobenzoic acid; amoxicillin; ampicillin; amsacrine; amsalog; anethole; ascorbic acid; aspartame; astemizole; atenolol; azatadine and its maleate; bacitracin; balsam peru; beclomethasone dipropionate; benzocaine; benzoic acid; benzophenones; benzoyl peroxide; benzquinamide and its hydrochloride; bethanechol; biotin; bisacodyl; bismuth subsalicylate; bornyl acetate; brompheniramine and its maleate; buspirone; caffeine; calamine; calcium carbonate, caseinate and hydroxide; camphor; captopril; carmustine; cascara sagrada; castor oil; cefaclor; cefadroxil; cephalexin; centrizine and its hydrochloride; cetirizine; cetyl alcohol; cetylpyridinium chloride; chelated minerals; chloramphenicol; chlorcyclizine hydrochloride; chlorhexidine gluconate; chloroxylenol; chloropentostatin; chlorpheniramine and its maleate and tannate salts; chlorpromazine; cholestyramine resin; choline bitartrate; chondrogenic stimulating protein; cimetidine; cinnamedrine hydrochloride; citalopram; citric acid; clarithromycin; clemastine and its fumarate; clonidine; clofibrate; cocoa butter; cod liver oil; codeine and its fumarate and phosphate; cortisone acetate; ciprofloxacin HCl; cyanocobalamin; cyclizine hydrochloride; cyproheptadine; danthron; dexbrompheniramine maleate; dextromethorphan and its hydrohalides; diazepam; dibucaine; dichloralphenazone; diclofenac sodium; digoxin; dihydroergotamine and its hydrogenates/mesylates; diltiazem; dimethicone; dioxybenzone; diphenhydramine and its citrate salt; diphenhydramine and its hydrochloride; divalproex and its alkali metal salts; docusate calcium, potassium, and sodium; doxycycline hydrate; doxylamine succinate; dronabinol; efaroxan; enalapril; enoxacin; ergotamine and its tartrate; erythromycin; estropipate; ethinyl estradiol; ephedrine; epinephrine bitartrate; erythropoietin; eucalyptol; famotidine; fenopropfen and its metal salts; ferrous fumarate, gluconate and sulfate; fexofenadine; fluoxetine; folic acid; fosphenytoin; 5-fluorouracil (5-FU); fluoxetine; flurbiprofen; furosemide; gabapentin; gentamicin; gemfibrozil; glipizide; glycerin; glyceryl stearate; granisetron; griseofulvin; growth hormone; guaifenesin; hexylresorcinol; hydrochlorothiazide; hydrocodone and its tartrates; hydrocortisone and its acetate; 8-hydroxyquinoline sulfate; hydroxyzine and its pamoate and hydrochloride salts; ibuprofen; indomethacin; inositol; insulin; iodine; ipecac; iron; isosorbide and its mono- and di-nitrates; isoxicam; ketamine; kaolin; ketoprofen; lactic acid; lactase; lanolin; lecithin; leuprolide acetate; lidocaine and its hydrochloride salt; lisinopril; liotrix; loperamide; loratadine; lovastatin; luteinizing hormone; LHRH (luteinizing hormone replacement hormone); magnesium

carbonate, hydroxide, salicylate, and trisilicate; meclizine; mefenamic acid; meclofenamic acid; meclofenamate sodium; medroxyprogesterone acetate; methenamine mandelate; menthol; meperidine hydrochloride; metaproterenol sulfate; methscopolamine and its nitrates; methysergide and its maleate; methyl nicotinate; methyl salicylate; methyl cellulose; methsuximide; metoclopramide and its halides/hydrates; metronidazole; metoprol tartrate; miconazole nitrate; mineral oil; minoxidil; morphine; naproxen and its alkali metal sodium salts; nifedipine; neomycin sulfate; niacin; niacinamide; nicotine; nicotinamide; nimesulide; nitroglycerin; nonoxynol-9; norethindrone and its acetate; nystatin; octoxynol; octoxynol-9; octyl dimethyl PABA; octyl methoxycinnamate; olsalazine; omega-3 polyunsaturated fatty acids; omeprazole; ondansetron and its hydrochloride; oxolinic acid; oxybenzone; oxtriphylline; para-aminobenzoic acid (PABA); padimate-O; paramethadione; pentostatin; peppermint oil; pentaerythritol tetranitrate; pentobarbital sodium; perphenazine; phenelzine sulfate; phenindamine and its tartrate; pheniramine maleate; phenobarbital; phenol; phenolphthalein; phenylephrine and its tannates and hydrochlorides; phenylpropanolamine; phenytoin; pirmenol; piroxicam and its salts; polydimethylsiloxanes; polymixin B sulfate; potassium chloride and nitrate; prazepam; procainamide hydrochloride; procaterol; promethazine and its hydrochloride; propoxyphene and its hydrochloride and napsylate; pramiracetam; pramoxine and its hydrochloride salt; prochlorperazine and its maleate; propranolol and its hydrochloride; promethazine and its hydrochloride; propranolol; pseudoephedrine and its sulfates and hydrochlorides; pyridoxine; pyrilamine and its hydrochlorides and tannates; quinapril; quinidine gluconate and sulfate; quinestrol; ranitidine; resorcinol; riboflavin; salicylic acid; scopolamine; sesame oil; shark liver oil; simethicone; sodium bicarbonate, citrate, and fluoride; sucalfate; sulfamethoxazole; sulfasalazine; sulfur; sumatriptan and its succinate; tacrine and its hydrochloride; theophylline; terfenadine; thiethylperazine and its maleate; timolol and its maleate; tioperidone; tramadol; trimetrexate; triazolam; tretinoin; tetracycline hydrochloride; tolmetin; tolnaftate; triclosan; trimethobenzamide and its hydrochloride; tripeleminamine and its hydrochloride; triprolidine hydrochloride; undecylenic acid; vancomycin; verapamil hydrochloride; vidarabine phosphate; vitamins and minerals; witch hazel; xylometazoline hydrochloride; zinc; zinc sulfate; zinc undecylenate. Active agents may further include, but are not limited to food acids; insoluble metal and mineral hydroxides, carbonates, oxides, polycarbophils, and salts thereof; adsorbates of active drugs on a magnesium trisilicate base and on a magnesium aluminum silicate base, and mixtures thereof. Mixtures and pharmaceutically acceptable salts of these and other actives can be used.

**[0016]** Examples of suitable active agents include stimulant laxatives, such as bisacodyl, cascara sagrada, danthron, senna, phenolphthalein, aloe, castor oil, ricinoleic acid, and dehydrocholic acid, and mixtures thereof; antisecretory; H<sub>2</sub> receptor antagonists, such as famotadine, which is commercially available from McNeil-PPC, Inc. under the PEPCID brand; proton pump inhibitors; gastrointestinal cytoprotectives, such as sucralfate and misoprostol; gastrointestinal prokinetics, such as Prucalopride, antibiotics for *H. pylori*, such as clarithromycin, amoxicillin, tetracycline, and metronidazole; antidiarrheals, such as diphenoxylate and loperamide, which is commercially available from McNeil-PPC, Inc. under the IMMODIUM brand; glycopyrrolate, such as Robinul; antiemetics, such as Ondansetron, analgesics, such as mesalamine, commercially available under the ASACOL brand, aspirin, and salicylic acid; and mixtures thereof.

**[0017]** In one embodiment, the additional active agent may be selected from bisacodyl, famotadine, prucalopride, diphenoxylate, loperamide, lactase, mesalamine, bismuth, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.

**[0018]** In another embodiment, the additional active agent may be selected from acetaminophen, ibuprofen, naproxen, ketoprofen, cyclobenzaprine, meloxicam, rofecoxib, celecoxib, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.

**[0019]** Examples of suitable polydimethylsiloxanes, which include, but are not limited to dimethicone and simethicone, are those disclosed in US Patent No. 4,906,478, US Patent No. 5,275,822, and US Patent No. 6,103,260, the contents of each is expressly incorporated herein by reference. As used herein, the term simethicone refers to the broader class of polydimethylsiloxanes, including simethicone and dimethicone.

**[0020]** Suitable lactase for use herein include, a lactase isolated from *Saccharomyces lactis*, by Gist-Brocade in Delft, Holland, and sold by Enzyme Development Corporation, New York, N.Y.; a lactase from *Aspergillus oryzae*, Lactase Y-400, produced by K. K. Yakult Honsha; a lactase from *Aspergillus oryzae*, Plexazym LA 1, produced by Roehm GmbH; a lactase from *Aspergillus oryzae*, produced by Shinnihon Kagaku Kogyo Co.; a lactase from *Kluyveromyces fragilis*, produced by Sturges Enzymes, Selby, North Yorkshire, England; a lactase from *Aspergillus oryzae*, Takamine lactase, produced by Miles Laboratories, Inc., Elkhart, IN.; a lactase from *Kluyveromyces fragilis* produced by Novo Enzymes, Bagsvaerd, Denmark, and a lactase from *Aspergillus oryzae*, e.g., Lactase F "Amano" 100, produced by Amano Pharmaceutical Co., Ltd. Naka-ku, Nagoya, Japan. These suppliers and others offer, generally, lactase composition, including a diluent, having a potency of between 14,000 and 100,000 FCC lactase units/gram.

**[0021]** The active agent can be in the form of a fine powder, granule, or large crystal, and has an average particle size from about 1  $\mu\text{m}$  to about 1000  $\mu\text{m}$ , also from about 150  $\mu\text{m}$  to about 500  $\mu\text{m}$ . Typically, the active agent used in the present invention has an average size of greater than 50  $\mu\text{m}$ .

**[0022]** If the active agent has an objectionable taste, it may be coated with a taste masking coating, as known in the art. Examples of suitable taste masking coatings are described in U.S. Patent No. 4,851,226, U.S. Patent No. 5,075,114,



and U.S. Patent No. 5,489,436. Commercially available taste masked active agents may also be employed. For example, acetaminophen particles that are encapsulated with ethylcellulose or other polymers by a coaccervation process may be used in the present invention. Coaccervation-encapsulated acetaminophen may be purchased from Eurand America, Inc. Vandalia, Ohio, or from Circa, Inc., Dayton, Ohio.

**[0023]** As used herein, all ranges provided are intended to expressly include at least all numbers that fall between the endpoints of ranges.

**[0024]** As used herein, simethicone conforms to the United States Pharmacopoeia (USP XXII) definition, that is a mixture of fully methylated linear siloxane polymers containing repeating units of polydimethylsiloxane stabilized with trimethylsiloxy end-blocking units, and silicon dioxide. Also, as used herein, dimethicone can be substituted for simethicone. Simethicone contains about 90.5-99% of polydimethylsiloxane and about 4-7% silicon dioxide. The polydimethylsiloxanes present in simethicone are practically inert polymers having a molecular weight of 14,000-21,000. The mixture is a gray, translucent, viscous fluid that is insoluble in water.

**[0025]** Conventional excipients useful in the present include fillers or dry binders, such as water soluble simple and complex carbohydrate (e.g., sucrose, glucose, fructose, maltose, lactose, maltodextrins, starch, modified starches, mannitol, sorbitol, maltitol, xylitol, and erythritol), cellulose, and cellulosic derivatives (e.g., microcrystalline cellulose, carboxymethyl cellulose, and hydroxyethyl cellulose); wet binders, such as polyvinyl pyrrolidone, methycellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, carboxymethylcellulose, xanthan gum, carrageenan gum, locust bean gum, alginates, and acacia; disintegrants, such as sodium starch glycolate, croscopolone, croscarmellose, microcrystalline cellulose, starch, and the like, lubricants, such as magnesium stearate, stearic acid and its pharmaceutically acceptable salts, talc, vegetable oils, and waxes; glidants, such as colloidal silicon dioxide; sweeteners, including aspartame, acesulfame potassium, sucralose and saccharin; flavors, acidulants, antioxidants, preservatives, surfactants, wetting agents, and coloring agents, and mixtures thereof.

**[0026]** As used herein, the term "adsorbant" means a solid material or combination of solid materials that is capable of adsorbing and carrying an oily or fluid material, such as simethicone, while retaining sufficient flowability to assure content uniformity and sufficient compactability to be processed into tablets using direct compression methods.

**[0027]** As used in the present invention, silicified microcrystalline cellulose may be the PROSOLV brand (PenWest Pharmaceuticals, Patterson, NY).

**[0028]** As used herein magnesium aluminometasilicate may be the NEUSILIN brand, e.g., S1 FH2, US2, and UFL2 (Fuji Chemical Industries (USA) Inc., Robbinsville, NJ).

**[0029]** In accordance with one embodiment of the present invention, simethicone is admixed with the magnesium aluminometasilicate to form a uniform free flowing granular admixture. The silicified microcrystalline cellulose is then added, as well as any optional additional active agent, and any additional excipients. The composition is then mixed until uniform. The resulting granular composition is then compressed.

**[0030]** In embodiments wherein one or more additional active agents are included, the additional active agent may optionally be admixed with the simethicone prior to adsorbing onto the magnesium aluminometasilicate and silicified microcrystalline cellulose. The resulting blend is then further blended with any additional active agents and any additional excipients, and compressed into tablets.

**[0031]** Generally, it is desired that the composition contains a proportionate amount of simethicone, magnesium aluminometasilicate, and silicified microcrystalline cellulose, which is consistent with forming a free-flowing granular composition. For example, the proportionate amounts, by weight, of the ingredients of the granular admixture composition is about 1: about 0.5 to about 0.85: about 0.9 to about 1.30 per solid dosage unit (simethicone:magnesium aluminometasilicate:silicified microcrystalline cellulose).

**[0032]** The weight ratio of simethicone to total adsorbant (e.g. magnesium aluminometasilicate and silicified microcrystalline cellulose) is at least about 1:2.22, for example at least about 1:2.00, or at least about 1:1.80. In one embodiment, the weight ratio of simethicone to total adsorbant is at least about 1 part simethicone to 1.75 parts adsorbant.

**[0033]** The solid dosage forms of the present invention may be shaped, in other words, formed, by a variety of methods known in the art. Optionally, the dosage form of the present invention, either with or without active agent, can be molded, deposited or compacted under methods commonly known in the art.

**[0034]** Solid dosage forms of the present invention may be formed by direct compression. Using this technique, the solid dosage forms are produced by directly compacting a blend of the active agent and any other appropriate inactive ingredients, i.e., excipients (e.g. flavoring, binders, lubricants, etc.). Any conventional compacting methods for forming a chewable dosage form may be used to make the soft core of the present invention. These methods include, but are not limited to, dry granulation followed by compression, and wet granulation followed by drying and compression. Compression methods include rotary compression, compacting roller technology, such as chilsonator or drop roller, or by molding, casting or extrusion technologies. These methods are well known in the art, and are described in detail in, for example, Lachman, et al., *The Theory and Practice of Industrial Pharmacy*, Chapter 11, (3<sup>rd</sup> Ed. 1986).

**[0035]** One such method utilizes placing a pre-determined volume of particles or components into a die cavity of a rotary tablet press, which continuously rotates as part of a die table from the filling position to a compaction position.

At the compaction position, the particles are compacted between an upper punch and a lower punch. The die table then rotates to an ejection position, at which the resulting tablet is pushed from the die cavity by the lower punch and guided to an ejection chute by a stationary take-off bar.

One aspect of the present invention is a compressed solid dosage form, e.g., a tablet or a caplet. The hardness of the solid dosage form is up to about 20 kiloponds per square centimeter (kp/cm<sup>2</sup>), e.g., about 2 to 15 kp/cm<sup>2</sup> or about 4 to 10 kp/cm<sup>2</sup>. As used herein, the term hardness is used to describe the diametral breaking strength as measured by conventional pharmaceutical hardness testing equipment, such as a Schleuniger Hardness Tester. In order to compare values across different size tablets, the breaking strength is normalized for the area of the break (which may be expressed in kp/cm<sup>2</sup>, and is sometimes referred in the art as tablet tensile strength. A general discussion of tablet hardness testing is found in Leiberman et al., *Pharmaceutical Dosage Forms - Tablets*, Volume 2, 2<sup>nd</sup> ed., Marcel Dekker Inc., 1990, pp. 213- 217, 327 - 329.

**[0036]** The solid oral dosage forms of the present invention may be prepared in the form of tablets, caplets, gelcaps, capsules, chewable tablets, lozenges, fast dissolving wafers, and other known and effective solid oral delivery modes.

**[0037]** A typical solid dosage form of the present invention may contain a formulation containing various components in accordance with the following:

Simethicone	about 1 to about 75 %
Silicified microcrystalline cellulose	about 5 to about 40%
Magnesium aluminometasilicate	about 5 to about 30%
Additional Active agent	about 0 to about 89%
Lubricant	about 0 to about 5%
Filler/dry binder	about 0 to about 35%
Wet Binder	about 0 to about 10%
Flavorants/Colorants/Sweeteners	about 0 to about 5%

All % are w/w%.

**[0038]** Specific embodiments of the present invention are illustrated by way of the following examples. This invention is not confined to the specific limitations set forth in these examples, but rather to the scope of the appended claims. Unless otherwise stated, the percentages and ratios given below are by weight.

## EXAMPLES

### Example 1:

**[0039]**

Ingredients	Unit Wt (mg)	% (w/w)	Batch Wt (g)
Simethicone**	135	33.75	337.5
Magnesium aluminometasilicate (NEUSILIN, US-2 from Fuji Chemical Ltd.)	77	19.25	192.5
Silicified microcrystalline cellulose (PROSOLV HD-90, from PenWest Co.)	150	37.5	375.0
Loperamide, USP	2	0.5	5
Sodium starch glycolate, NF	32	8	80
Stearic acid, NF	4	1	10
TOTAL			1000

\*\*Note: 10% overage added

**[0040]** In a 4 quart Hobart mixer, the magnesium aluminometasilicate and one-half of the batch quantity of the silicified microcrystalline cellulose were combined with the simethicone by initially sandwiching the simethicone between the magnesium aluminometasilicate (bottom) and the silicified microcrystalline cellulose (top) and mixed at speed setting "1" for about 5 minutes.

## EP 1 297 825 A1

**[0041]** The loperamide was screened using a No. 40 mesh screen. After screening, the loperamine, sodium starch glycolate and remaining silicified microcrystalline cellulose were added to Hobart mixer and mixed at speed setting "1" for about 5 minutes.

**[0042]** The stearic acid was screened using a No. 30 mesh screen. After screening, the stearic acid was added to the Hobart mixer and mixed for about five minutes to form a free-flowing compressible powder.

**[0043]** The powder was then compressed into individual units, e.g., tablets, on a Manesty Beta Press with caplet shape standard concave tooling (diameter = 6.092 mm, length = 19.995 mm) through pre-compression at 5 kN followed by main compression. The target weight per unit was 400 mg. Each unit was measure for total weight, thickness (mm) and hardness (Kp) at various compression forces. Such data is presented below.

Main Compression Force (kN)	Weight of 10 Units (g)	Average Thickness (mm)	Average Hardness (kp/cm <sup>2</sup> )
5	4.037	5.135	5.75
10	3.990	4.943	6.64
12.5	3.947	4.814	7.5
15	3.906*	4.743	5.88
20	3.912*	4.687	5.95

\* some picking upon compression.

### Example 2: Simethicone (120 mg) Loperamide (2 mg) Caplets:

**[0044]**

Ingredients	Unit Wt (mg)	% (w/w)	Batch Wt (g)
Simethicone	135	33.75	33.75
Magnesium aluminometasilicatealuminometasilicate (NEUSILIN, US-2 from Fuji Chemical Ltd.)	85	21.25	21.25
Silicified microcrystalline cellulose (PROSOLV HD-90, from PenWest Co.)	150	37.5	37.5
Loperamide, USP	2	0.5	0.5
Sodium starch glycolate, NF	26	6.5	6.5
Stearic acid, NF	2	0.5	0.5
TOTAL			100

**[0045]** In a glass mortar and pestle, the simethicone was levigated into the magnesium aluminometasilicate. The silicified microcrystalline cellulose was added to the dry simethicone/magnesium aluminometasilicate mixture and mixed thoroughly. The loperamide and sodium starch glycolate were added while mixing until uniform. The stearic acid was added and mixing was continued for about five minutes.

**[0046]** The powder was then compressed into individual units, e.g., tablets, on a Manesty Beta Press with caplet shape standard concave tooling (diameter = 6.092 mm, length = 19.995 mm) through pre-compression at 5 kN followed by main compression. Each unit was measured for total weight, thickness (mm) and hardness (kp) at various compression forces. Such data is presented below.

Main Compression Force (kN)	Average Weight of Three Units (mg)	Average Thickness of Three Units (mm)	Average Hardness of Three Units (kp/cm <sup>2</sup> )
3.5	421	5.602	10.16
5	424	5.29	9.62
7	410	4.601	5.71

## EP 1 297 825 A1

(continued)

Main Compression Force (kN)	Average Weight of Three Units (mg)	Average Thickness of Three Units (mm)	Average Hardness of Three Units (kp/cm <sup>2</sup> )
10	418.3	5.129	7.68
18	402.7	4.89	5.37

### **Example 3 Simethicone (120 mg) Loperamide (2 mg) Caplets:**

**[0047]**

Ingredients	Unit Wt (mg)	% (w/w)	Batch Wt (g)
Simethicone	135	31.034	62.1
Magnesium aluminometasilicate (NEUSILIN, US-2 from Fuji Chemical Lt)	105	24.138	48.3
Silicified microcrystalline cellulose (PROSOLV HD-90, from PenWest Co.)	170	39.08	78.2
Loperamide, USP	2	0.4598	0.9
Sodium starch glycolate, NF	20	4.5977	9.2
Stearic acid, NF	3	0.6897	1.4
TOTAL			200

**[0048]** In a 4 quart Hobart mixer, the magnesium aluminometasilicate and one-half of the batch quantity of the silicified microcrystalline cellulose were combined with the simethicone by initially sandwiching the simethicone between the magnesium aluminometasilicate (bottom) and the silicified microcrystalline cellulose (top) and mixed at speed setting No. 1 for about 5 minutes.

**[0049]** The loperamide was screened using a No. 40 mesh screen. After screening, loperamide, sodium starch glycolate and remaining silicified microcrystalline cellulose were added to Hobart mixer and mixed at speed setting "1" for about 5 minutes.

**[0050]** The stearic acid was screened using a No. 30 mesh screen. After screening, the stearic acid was added to the Hobart mixer and mixed for about five minutes to form a free-flowing compressible powder.

**[0051]** The powder was then compressed into individual units, e.g., tablets, on a Manesty Beta Press with caplet shape standard concave tooling (diameter = 6.092 mm, length = 19.995 mm) through pre-compression at 3 kN followed by main compression. Each unit was measure for total weight, thickness (mm) and hardness (kp) at various compression forces. Such data is presented below.

Main Compression Force (kN)	Average Weight of Five Units (mg)	Average Thickness of Five Units (mm)	Average Hardness of Five Units (kp/cm <sup>2</sup> )
1	405	5.994	11.50
3.4	404.4	5.7522	15.24
5.0	371.6	5.129	15.87
6.0	390.2	5.145	17.23
7.5	394	5.164	15.26
10	390.6	4.874	13.13
13	386.4	4.763	10.30
20	397.8	4.795	8.18

**[0052]** While the target weight per unit was 435 mg, with tooling (604 x 224 x 052 BB caplet), i.e., volume of die at



maximum, only about 400 mg weight was possible.

#### **EXAMPLE 4:**

**[0053]** A disintegration test comparing a unit from Example 1, (pre-compression 5 kN and main compression 5 kN) and a unit from Example 3 (pre-compression 3 kN and main compression 5 kN) in water was carried out. The results showed that the Example 1 unit disintegrated in less than about 2 minutes after the unit was placed in water, while the Example 3 unit remained intact and was floating in the water after about 2 and one-half minutes.

#### **Example 5 Simethicone (120 mg) Loperamide (2 mg) Caplets:**

##### **[0054]**

Ingredients	Unit Wt (mg)	% (w/w)	Batch Wt (g)
Simethicone*	135	33.75	67.5
Magnesium aluminometasilicate (NEUSILIN, US-2 from Fuji Chemical Ltd.)	90	22.5	45
Silicified microcrystalline cellulose (PROSOLV HD-90, from PenWest Co.)	150	37.5	75
Loperamide, USP	2	0.5	1
Sodium starch glycolate, NF	20	5	10
Stearic acid, NF	3	0.75	10
TOTAL			200

\* Note: 10% overage added

**[0055]** In a 4 quart Hobart mixer bowl, simethicone was slowly added to about one-half of the batch quantity of the magnesium aluminometasilicate and mixed with a spatula for about 5 minutes.

**[0056]** The remaining magnesium aluminometasilicate was added to the mixture and mixing continued until the uniform, scraping the sides of the bowl.

**[0057]** The loperamide was screened using a No. 40 mesh screen. After screening, loperamide, sodium starch glycolate and the silicified microcrystalline cellulose were added. The resulting mixture was mixed at speed setting "1" for about five minutes.

**[0058]** The stearic acid was screened using a No. 30 mesh screen. After screening, the stearic acid was added and mixed for about five minutes to form a free-flowing compressible powder.

**[0059]** The powder was then compressed into individual units, e.g., tablets, on a Manesty Beta Press with caplet shape standard concave tooling (diameter = 6.092 mm, length = 19.995 mm) through pre-compression at 3 kN followed by main compression. Target weight was 400 mg per unit. Each unit was measure for total weight, thickness (mm) and hardness (kp) at various compression forces. Such data is presented below.

Main Compression Force (kN)	Average Weight of Five Units (mg)	Average Thickness of Five Units (mm)	Average Hardness of Five Units (kp/cm <sup>2</sup> )
1	397.4	5.920	6.60
3.0	396.6	5.572	9.66
5.0	396.6	5.263	9.67
6.0	399.6	5.156	9.30
7.0	395.6	5.018	8.37
90	396.2	4.974	8.45
12.5	389.4	4.806	7.24
20.0	372.4	4.655	<4.94

## EP 1 297 825 A1

### Example 6 Simethicone (120 mg) Loperamide (2 mg) Caplets:

[0060]

Ingredients	Unit Wt (mg)	% (w/w)	Batch Wt (g)
Simethicone	135	33.75	67.5
Magnesium aluminometasilicate (NEUSILIN, US-2 from Fuji Chemical Ltd)	100	25	50
Silicified microcrystalline cellulose (PROSOLV HD-90, from PenWest Co.)	140	35	70
Looperamide, USP	2	0.5	1
Sodium starch glycolate, NF	20	5	10
Stearic acid, NF	3	0.75	10
TOTAL			200

[0061] In a 4 quart Hobart mixer bowl, simethicone was slowly added to about one-half of the batch quantity of the magnesium aluminometasilicate and mixed with a spatula for about 5 minutes.

[0062] The remaining magnesium aluminometasilicate was added to the mixture and mixing continued until the uniform, scraping the sides of the bowl.

[0063] The looperamide was screened using a No. 40 mesh screen. After screening, looperamide, sodium starch glycolate and the silicified microcrystalline cellulose were added. The resulting mixture was mixed at speed setting "1" for about five minutes.

[0064] The stearic acid was screened using a No. 30 mesh screen. After screening, the stearic acid was added and mixed for about five minutes to form a free-flowing compressible powder.

[0065] The powder was then compressed into individual units, e.g., tablets, on a Manesty Beta Press with caplet shape standard concave tooling (diameter = 6.092 mm, length = 19.995 mm) through pre-compression at 3 kN followed by main compression. Target weight was 400 mg per unit. Each unit was measure for total weight, thickness (mm) and hardness (kp) at various compression forces. Such data is presented below.

Main Compression Force (kN)	Weight of Five Units (mg)	Average Thickness of Five Units (mm)	Average Hardness of Five Units (kp/cm <sup>2</sup> )
1	395.6	5.773	6.94
2.0	398.2	5.672	8.57
3.0	400	5.263	10.23
4.0	395.8	5.296	7.81
5.0	390.8	5.1128	8.48
10	397.6	4.975	<7.26
20	374.8	4.671	7.10

### Example 7 Simethicone (120 mg) Loperamide (2 mg) Caplets:

[0066]

Ingredients	Unit Wt (mg)	% (w/w)	Batch Wt (g)
Simethicone	135	33.75	67.5
Magnesium aluminometasilicate (NEUSILIN, US-2 from Fuji Chemical Ltd)	110	27.5	55

# EP 1 297 825 A1

(continued)

Ingredients	Unit Wt (mg)	% (w/w)	Batch Wt (g)
Silicified microcrystalline cellulose (PROSOLV HD-90, from PenWest Co.)	125	31.25	62.5
Loperamide, USP	2	0.5	1
Sodium starch glycolate, NF	25	6.25	12.5
Stearic acid, NF	3	0.75	1.5
TOTAL			200

[0067] In a 4 quart Hobart mixer bowl, simethicone was slowly added to about one-half of the batch quantity of the magnesium aluminometasilicate and mixed with a spatula for about 5 minutes.

[0068] The remaining magnesium aluminometasilicate was added to the mixture and mixing continued until the uniform, scraping the sides of the bowl.

[0069] The loperamide was screened using a No. 40 mesh screen. After screening, the loperamine, sodium starch glycolate and the silicified microcrystalline cellulose were added. The resulting mixture was mixed at speed setting "1" for about five minutes.

[0070] The stearic acid was screened using a No. 30 mesh screen. After screening, the stearic acid was added and mixed for about five minutes to form a free-flowing compressible powder.

[0071] The powder was then compressed into individual units, e.g., tablets, on a Manesty Beta Press with caplet shape standard concave tooling (diameter = 6.092 mm, length = 19.995 mm) through pre-compression at 3 kN followed by main compression. Each unit was measure for total weight, thickness (mm) and hardness (kp) at various compression forces. Such data is presented below.

Main Compression Force (kN)	Average Weight of Five Units (mg)	Average Thickness of Five Units (mm)	Average Hardness of Five Units (kp/cm <sup>2</sup> )
1	399	5.935	7.47
2	398.8	5.898	7.68
3.0	404.2	5.709	8.74
4.0	408	5.438	9.60
5.0	408.8	5.344	9.46
10.0	408.6	5.090	5.80
15.0	405.8	4.944	<4.45
20.0	400.8	4.8716	<4.04

## Example 8 Simethicone (120 mg) Loperamide (2 mg) Caplets:

[0072]

Ingredients	Unit Wt (mg)	% (w/w)	Batch Wt (g)
Simethicone**	135	35.065	140.3
Magnesium aluminometasilicate (NEUSILIN, US-2 from Fuji Chemical Ltd)	90	23.377	93.5
Silicified microcrystalline cellulose (PROSOLV HD-90 from PenWest Co.)	146	37.922	151.7

\*\* Note: 10% overage added

# EP 1 297 825 A1

(continued)

Ingredients	Unit Wt (mg)	% (w/w)	Batch Wt (g)
Loperamide, USP	2	0.520	2.1
Sodium starch glycolate, NF	10	2.597	10.4
Stearic acid, NF	2	0.520	2.1
TOTAL			400

**[0073]** In a 4 quart Hobart mixer bowl, simethicone was slowly added to about one-half of the batch quantity of the magnesium aluminometasilicate and mixed with a spatula for about 5 minutes.

**[0074]** The remaining magnesium aluminometasilicate was added to the mixture and mixing continued until the uniform, scraping the sides of the bowl.

**[0075]** The loperamide was screened using a No. 40 mesh screen. After screening, the loperamine, sodium starch glycolate, NF and the silicified microcrystalline cellulose were added. The resulting mixture was mixed at speed setting "1" for about five minutes.

**[0076]** The stearic acid was screened using a No. 30 mesh screen. After screening, the stearic acid was added and mixed for about five minutes to form a free-flowing compressible powder.

**[0077]** The powder was then compressed into individual units, e.g., tablets, on a Manesty Beta Press with caplet shape standard concave tooling (diameter = 6.092 mm, length = 19.995 mm) through pre-compression at 3 kN followed by main compression (\* these units were not pre-compressed). Target weight was 385 mg per unit. Each unit was measure for total weight, thickness (mm) and hardness (kp) at various compression forces. Such data is presented below.

Main Compression Force (kN)	Average Weight of Five Units (mg)	Average Thickness of Five Units (mm)	Average Hardness of Five Units (kp/cm2)
1	382.8	5.460	9.56
2	383.4	5.395	9.31
3.0	382	5.356	7.60
4.0	379.8	5.123	8.78
5.0	382.8	4.993	<6.58
10.0	383.6	4.841	<4.07
1.5*	384.8	5.439	7.12
3.0*	382.4	5.306	7.61

## Example 9 Simethicone (120 mg) / Acetaminophen (250 mg) Caplets:

**[0078]**

Ingredients	Unit Wt (mg)
Simethicone**	135
Magnesium aluminometasilicate (NEUSILIN, US-2 from Fuji Chemical Ltd)	90
Silicified microcrystalline cellulose (PROSOLV HD-90 from PenWest Co.)	150
Acetaminophen, USP	250
Sodium starch glycolate, NF	20
Stearic acid, NF	5
TOTAL	650

\*\* Note: 10% overage added



## EP 1 297 825 A1

[0079] In a 4 quart Hobart mixer bowl, simethicone is slowly added to about one-half of the batch quantity of the magnesium aluminometasilicate with mixing using a spatula for about 5 minutes.

[0080] The remaining magnesium aluminometasilicate is added to the mixture and mixing continued until the uniform, scraping the sides of the bowl.

[0081] The acetaminophen is screened using a No. 40 mesh screen. After screening, the acetaminophen, sodium starch glycolate, NF and the silicified microcrystalline cellulose are added. The resulting mixture is mixed at speed setting "1" for about five minutes.

[0082] The stearic acid is screened using a No. 30 mesh screen. After screening, the stearic acid is added and mixed for about five minutes to form a free-flowing compressible powder.

### Example 10 Simethicone (120 mg) / Ibuprofen (200 mg) Caplets:

[0083]

Ingredients	Unit Wt (mg)
Simethicone**	135
Magnesium aluminometasilicate (NEUSILIN, US-2 from Fuji Chemical Ltd)	90
Silicified microcrystalline cellulose (PROSOLV HD-90 from PenWest Co.)	150
Ibuprofen, USP	200
Sodium starch glycolate, NF	20
Stearic acid, NF	5
TOTAL	600

\*\* Note: 10% overage added

[0084] In a 4 quart Hobart mixer bowl, simethicone is slowly added to about one-half of the batch quantity of the magnesium aluminometasilicate with mixing using a spatula for about 5 minutes.

[0085] The remaining magnesium aluminometasilicate is added to the mixture and mixing continued until the uniform, scraping the sides of the bowl.

[0086] The ibuprofen is screened using a No. 40 mesh screen. After screening, the ibuprofen, sodium starch glycolate, NF and the silicified microcrystalline cellulose are added. The resulting mixture is mixed at speed setting "1" for about five minutes.

[0087] The stearic acid is screened using a No. 30 mesh screen. After screening, the stearic acid is added and mixed for about five minutes to form a free-flowing compressible powder.

### Example 11 Simethicone (120 mg) / Mesalamine (400 mg) Caplets:

[0088]

Ingredients	Unit Wt (mg)
Simethicone**	135
Magnesium aluminometasilicate (NEUSILIN, US-2 from Fuji Chemical Ltd)	110
Silicified microcrystalline cellulose (PROSOLV HD-90 from PenWest Co.)	125
Mesalamine (5-aminosalicylic acid, 5-ASA)	2
Stearic acid, NF	10
TOTAL	781

\*\* Note: 10% overage added

[0089] In a 4 quart Hobart mixer bowl, simethicone was slowly added to about one-half of the batch quantity of the magnesium aluminometasilicate and mixed with a spatula for about 5 minutes.

[0090] The remaining magnesium aluminometasilicate was added to the mixture and mixing continued until the uniform, scraping the sides of the bowl.

[0091] The mesalamine is screened using a No. 40 mesh screen. After screening, the mesalamine and the silicified microcrystalline cellulose are added. The resulting mixture was mixed at speed setting "1" for about five minutes.

[0092] The stearic acid is screened using a No. 30 mesh screen. After screening, the stearic acid is added and mixed for about five minutes to form a free-flowing compressible powder.

5

## Claims

10

1. A composition for forming a compressed solid dosage form comprising a free-flowing compressible admixture of simethicone and an adsorbant, wherein the weight ratio of simethicone to adsorbant is at least about 1:2.22.

2. A composition of claim 1, wherein the weight ratio of simethicone to adsorbant is at least about 1:2.00.

15

3. A composition of claim 1 or claim 2, wherein the adsorbant comprises a combination of silicified microcrystalline cellulose and magnesium aluminometasilicate.

20

4. A solid oral dosage form comprising a compressed admixture of simethicone, silicified microcrystalline cellulose, and magnesium aluminometasilicate, wherein the simethicone is adsorbed on the silicified microcrystalline cellulose and magnesium aluminometasilicate.

25

5. A solid oral dosage form of claim 4, wherein the weight ratio of simethicone to adsorbent is at least 1:2.00.

6. A composition of claim 3 or a dosage form of claim 4 or claim 5, having from 19 wt% to 27 wt% silicified microcrystalline cellulose and having from 31 wt% to 39 wt% magnesium aluminometasilicate, preferably having from 23 wt% to 27 wt% silicified microcrystalline cellulose and from 33wt% to 37 wt% magnesium aluminometasilicate.

7. A composition or dosage form of any one of claims 1 to 6, further comprising at least one additional active agent.

30

8. A composition or dosage form of claim 7, wherein the active agent is selected from the group consisting of bisacodyl, famotadine, prucalopride, diphenoxylate, loperamide, lactase, mesalamine, bismuth, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof and wherein the active agent preferably is loperamide, or pharmaceutically acceptable salts, esters, or isomers thereof or bisacodyl or pharmaceutically acceptable salts, esters, or isomers thereof.

35

9. A composition or dosage form of claim 7, wherein the active agent is selected from the group consisting of acetaminophen, ibuprofen, naproxen, ketoprofen, cyclobenzaprine, meloxicam, rofecoxib, celecoxib, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.

40

10. A composition or dosage form of any one of claims 1 to 9 having at least 30 wt% simethicone, preferably from 31 wt% to 35 wt% simethicone.

11. A composition or dosage form of any one of claims 1 to 10, wherein the composition is compressed into a tablet having a hardness value of at least 2 kp/cm<sup>2</sup>, preferably from 5 to 10 kp/cm<sup>2</sup>.

45

12. A composition for forming a solid dosage form comprising a free-flowing compressible admixture of simethicone, silicified microcrystalline cellulose and magnesium aluminometasilicate.

50

13. A compressed solid dosage form comprising an admixture of simethicone, silicified microcrystalline cellulose and magnesium aluminometasilicate, wherein the weight ratio of simethicone to adsorbent is at least 1:2.00.

55



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 02 25 6741

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	<p>DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KISSEI PHARMACEUTICAL CO., LTD., JAPAN: "Adsorbents for tableting oily materials" retrieved from STN Database accession no. 96:187285 HCA XP002225224 * abstract *</p> <p>&amp; JP 56 169622 A (KISSEI PHARMACEUTICAL CO., LTD., JAPAN) 26 December 1981 (1981-12-26)</p>	1,2	A61K9/14
X	<p>DATABASE WPI Section Ch, Week 200136 Derwent Publications Ltd., London, GB; Class A96, AN 1993-164356 XP002225225 &amp; JP 03 177707 B (HORII YAKUHHIN KOGYO KK), 18 June 2001 (2001-06-18) * abstract *</p>	1,2	
A	<p>US 5 458 886 A (BRIQUET FRANCOIS J) 17 October 1995 (1995-10-17) * examples *</p>	1	
A	<p>EP 0 659 403 A (NAT STARCH CHEM INVEST) 28 June 1995 (1995-06-28) * the whole document *</p>	1	
The present search report has been drawn up for all claims			
Place of search		Date of completion of the search	Examiner
THE HAGUE		17 December 2002	Boulois, D
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>			

PRO F.U.H.M. 1503 03 82 (P.4/301)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 02 25 6741

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

17-12-2002

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
JP 56169622	A	26-12-1981	JP	1029764 B	14-06-1989
			JP	1546837 C	28-02-1990
JP 3177707	B	20-04-1993	JP	3177707 B2	18-06-2001
			JP	5097681 A	20-04-1993
US 5458886	A	17-10-1995	FR	2705966 A1	09-12-1994
			DE	4419607 A1	08-12-1994
			GB	2279009 A , B	21-12-1994
			JP	7166062 A	27-06-1995
EP 0659403	A	28-06-1995	DE	69426863 D1	19-04-2001
			DE	69426863 T2	27-09-2001
			EP	0659403 A2	28-06-1995
			JP	2561447 B2	11-12-1996
			JP	7223973 A	22-08-1995

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82